Updated on 3 May 2012
Roche recently launched Pegasys Autoinjector that facilitates a quick, safe and convenient subcutaneous administration. This product is approved in the EU and the US markets.
"Development of a combination product provides an extra challenge technically to ensure compatibility of device and formulation. This relates to viscosity, stability and purity of the formulation administered with the device. Design of the device also needs to ensure easy and reliable handling of the product by the patient group it is being developed for," shares Ms Ursula Redeker, head, technical development biologics Europe, F Hoffmann-La Roche, while talking about regulations for combination products developed by Roche.